Streetbeat News

Equity Actions

ARGX

argenx has raised approximately $1.1 billion in gross proceeds from a global offering. The company sold 1,580,981 ADSs at a price of $490.00 per ADS and 663,918 ordinary shares at a price of €436.37 per ordinary share.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2023 | 4:52 am

GOOGL

META

MSFT

Meta Platforms Inc. (NASDAQ:META) CEO Mark Zuckerberg announced plans to open-source the company’s latest AI technology, LLaMA 2, to developers and software enthusiasts for free. This move could help Meta compete with rivals like Google (NASDAQ:GOOGL) and ChatGPT. Meta and Microsoft (NASDAQ:MSFT) have partnered to make LLaMA 2 open-source, allowing it to operate on Microsoft’s Azure cloud services.

Portfolio Pulse from Benzinga Neuro

July 19, 2023 | 4:08 am

ARKK

ARKW

AVDX

COIN

SOFI

TSLA

TWLO

Ark Invest, led by Cathie Wood, has continued to sell Tesla Inc shares for the second consecutive day, with the most significant trade involving the sale of 28,659 Tesla shares valued at $8.4 million. The firm sold shares through the Ark Innovation Fund and the Ark Next Generation Internet ETF. Despite this, Ark Invest remains bullish on Tesla's long-term prospects, particularly in AI. Other trades included the purchase of shares in Twilio Inc, AvidXchange Holdings Inc, and SoFi Technologies Inc, and the sale of Coinbase Global Inc shares.

Portfolio Pulse from Benzinga Neuro

July 19, 2023 | 1:21 am

MSSTF

REUN

Terran Biosciences has filed a patent application for solid forms of 4-OH-DiPT hemiglutarate, a psychedelic compound, amidst an ongoing court battle between Reunion Neuroscience (NASDAQ:REUN) and Mindset Pharma (OTC:MSSTF) over similar claims. Terran's application claims priority back to six provisional applications, including four filed just a week after the broad nature of RE104, Reunion's lead drug candidate, was disclosed.

Portfolio Pulse from Lara Goldstein

July 19, 2023 | 12:47 am

PHRRF

PharmaTher Holdings (OTCQB:PHRRF) and the Terasaki Institute for Biomedical Innovation have reported positive outcomes from their research on a novel microneedle patch for the delivery of DMT. The study aimed to develop a suitable prototype of PharmaPatch for DMT’s transdermal delivery. The company will work with its research partner PharmaDrug Inc., and invest $227,700 in PharmaDrug's subsidiary, Sairiyo Therapeutics, for a 49% ownership.

Portfolio Pulse from Lara Goldstein

July 18, 2023 | 9:45 pm

ODD

The Wall Street Journal has reported that Oddity's initial public offering (IPO) is set to price at $35 per share.

Portfolio Pulse from Charles Gross

July 18, 2023 | 9:28 pm

HHC

Howard Hughes Corporation has announced that its new holding company will trade under the ticker symbol 'HHH' starting from August 14, 2023. This follows the company's board of directors authorizing a holding company reorganization.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 9:25 pm

DMAQ

Deep Medicine Acquisition Corp. and Bright Vision Sponsor LLC have entered into non-redemption agreements with six unaffiliated third parties. The agreements pertain to a maximum of 514,773 shares of Class A common stock sold during the company's IPO, with the sponsor agreeing to transfer up to 185,179 shares upon completion of the company's initial business combination.

Portfolio Pulse from Charles Gross

July 18, 2023 | 9:19 pm

DIS

The Walt Disney Company (NYSE:DIS) has promoted Alexia Quadrani to Executive Vice President, Investor Relations. Quadrani will continue to serve as Disney's primary information liaison to the global investment community and will be responsible for expanding the company's relationships with investment analysts and investors worldwide. Prior to joining Disney, Quadrani served as Managing Director and Senior Analyst, U.S. Media Equity Research at J.P. Morgan for 14 years.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 9:01 pm

IAUX

i-80 GOLD CORP. (NYSE:IAUX) has announced a private placement of 11,852,000 common shares at a price of $2.70 per share, raising gross proceeds of $32.0 million. The company has also granted the underwriters an option to purchase up to an additional 15% of the offering. The net proceeds will be used for the exploration, development, and ramp-up of the Corporation's mineral projects and for general corporate purposes. The offering is expected to close on August 1, 2023.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 8:46 pm